Psoriasis | Epidemiology update 2012-2030.
'US to see most rapid rise in prevalence'
By Sabada Dube, Lead Epidemiologist
15 August 2013
I am the Lead Epidemiologist at Datamonitor Healthcare. I joined Datamonitor in 2007, having worked in different capacit...
Read full bio
Psoriasis is a chronic inflammatory skin disorder affecting 1–5% of the world’s population. It is a lifelong disease with low mortality but with high morbidity, and can severely affect quality of life. This content provides an in-depth epidemiologic analysis, estimate, and forecast of prevalent psoriasis patient populations in the US, Japan, France, Germany, Italy, Spain, and the UK up to 2030. The analysis further provides patient populations by key patient segments.
Psoriasis prevalent cases are expected to increase by the largest amount in the US, to a lesser extent in the five major EU markets (France, Germany, Italy, Spain, and the UK), and to decline slightly in Japan through to 2030.
Datamonitor Healthcare epidemiologists used proprietary forecasting methodology based on robust, population-based studies from the US, Japan, and five major EU markets to estimate and forecast psoriasis prevalence.
This is a Psoriasis analysis update from the Datamonitor Healthcare service, which provides regular and event-senstive research for key drugs and companies, treatment trends, patient populations and strategic issues.
- For more information on this research, please contact
- For current clients, please log-in to view the full analysis at: